Healthcare Sector Leads S&P 500 as Pharma Giants Navigate 2026 Market Shift

As of February 12, 2026, the healthcare sector has decisively seized the mantle of market leadership in the S&P 500. Since the final quarter of 2025, the healthcare sector has surged by a remarkable 10%, outpacing every other major industry group. Investors have executed a massive rotation, fleeing overextended tech valuations in favor of the stability and renewed growth prospects of healthcare value plays.

The path to healthcare's 2026 dominance began in earnest during a volatile Q4 2025. As the artificial intelligence fervor that propelled the "Magnificent Seven" began to show signs of exhaustion, institutional capital sought refuge in sectors with resilient cash flows and lower price-to-earnings ratios. The Healthcare Select Sector SPDR Fund became the primary beneficiary of this migration.

On January 1, 2026, the first set of negotiated Maximum Fair Prices for 10 blockbuster drugs took effect. While critics once feared these price cuts—ranging from 38% to 79%—would cripple the industry, the reality proved far less dire. Most major pharmaceutical companies had already adjusted their long-term guidance and R&D pipelines years in advance. By the time the prices went live, the "worst-case scenario" was already baked into stock prices, leaving room for a massive relief rally.

Eli Lilly and Company has emerged as the undisputed titan of the sector, becoming the first pharmaceutical firm to reach a $1 trillion market capitalization in early 2026. Driven by the stratospheric demand for its GLP-1 obesity and diabetes medications, Zepbound and Mounjaro, Lilly's stock is up over 60% over the last year. The company's mid-2026 roadmap includes the anticipated launch of the oral medication Orforglipron.

Merck & Co. has also secured a winning position, trading near $122 as of mid-February. Merck boasts more than six blockbuster drugs in its portfolio. Among these, immuno-oncology drug Keytruda accounts for 54% of total sales in 2025. The drug has played a pivotal role in driving top-line revenue growth over the past few years. Keytruda's sales rose around 7% in 2025.

The FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph injection) for subcutaneous administration in adults across most solid tumor indications for Keytruda in September 2025. Merck is currently evaluating Keytruda across a wide variety of cancers and treatment settings and targets peak sales of $35 billion by 2028. However, Keytruda will lose patient exclusivity in 2028, adversely impacting the top line.

By successfully extending the patent runway for its flagship cancer drug through new subcutaneous formulations and diversifying into rare diseases with the success of Winrevair, Merck has proven that the "patent cliff" can be managed. The pulmonary arterial hypertension drug, Winrevair, witnessed a strong launch and should drive significant growth in the long term.

Merck's other oncology drugs — Welireg, Lynparza (in partnership with AstraZeneca) and Lenvima — are also performing well and contributing to top-line growth. Merck's Animal Health business is a key contributor to its top-line growth, witnessing strong demand driven by the livestock portfolio.

Merck is also making efforts to strengthen its vaccine portfolio in the wake of declining Gardasil sales. Its new 21-valent pneumococcal conjugate vaccine, Capvaxive, has seen strong uptake. The company currently has approximately 80 ongoing late-stage studies. This has positioned Merck to launch around 20 drugs over the next few years, with many having blockbuster potential. The company now expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s.

The recent acquisition of Cidara Therapeutics and Verona Pharma has expanded its respiratory and infectious disease portfolios. However, Merck is seeing declining demand for its diabetes products (Januvia/Janumet) and the generic erosion of some drugs like Bridion and Dificid, and expects a headwind of approximately $2.5 billion from generic competition in 2026. The company also expects significantly lower sales of Lagevrio due to continued soft demand. Declining sales of Gardasil, Merck's second-largest product, pose another headwind, driven by weak demand in China and Japan.

AbbVie Inc. has defied skeptics by successfully backfilling the revenue lost from Humira's biosimilar competition with newer immunology hits like Skyrizi and Rinvoq.

Bristol Myers Squibb concentrates on developing breakthrough therapies across oncology, hematology, immunology, cardiovascular disease, neuroscience and beyond. The company's Growth Portfolio includes key brands, such as Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy.

Opdivo is approved for various oncology indications around the world, either as monotherapy or in combination with other drugs. Consistent label expansion of the drug has enabled it to maintain momentum. The approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous administration has further strengthened the company's IO franchise, with initial uptake proving robust across all approved tumor types in the United States. Sales of its oncology drug, Opdualag, have also been robust, fueling the top line.

Reblozyl, the thalassemia drug co-developed with Merck, continues to be a major growth driver, with annualized sales now exceeding $2 billion. Strong momentum in cardiovascular drug Camzyos has boosted the top line. Breyanzi sales have been strong as well.

While the newer drugs boost sales, generic competition for legacy drugs, which accounted for 45% of total revenues in 2025, is a significant headwind. Legacy Portfolio sales continue to decline due to the ongoing generic impact on Revlimid, Pomalyst, Sprycel and Abraxane.

Vinva Investment Management Ltd. significantly increased its holdings in Bristol Myers Squibb Company by 140.3% in the third quarter, according to a recent 13F filing with the SEC. The fund now owns 584,506 shares of the biopharmaceutical company's stock, valued at $25.8 million. Vinva Investment Management added 341,246 shares of Bristol Myers Squibb to its portfolio during the third quarter, bringing its total holdings to 584,506 shares.

The managed care space has faced a more difficult start to 2026. UnitedHealth Group, once the bedrock of the sector, has lagged significantly, with its stock price hovering around $339—a sharp decline from its 2024 peaks. The company has struggled with higher-than-anticipated medical utilization rates and less favorable Medicare Advantage reimbursement rates from the government. While the broader sector thrives on drug innovation, insurers like UnitedHealth and CVS Health are currently navigating a painful period of margin compression.

Throughout January 2026, the industry saw a flurry of multi-billion-dollar deals as pharmaceutical companies used their balance sheets to acquire specialized biotech firms, further fueling investor optimism. The integration of generative AI into drug development cycles has also contributed to the sector's renewed growth prospects.